提尔德拉基祖马布200毫克:在牛皮治疗方面迈出了一步,并增加了代谢益处
Caterina Lanna1, Antonia Rivieccio1, Chiara Cattani1
1Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
The Journal of dermatological treatment
|June 15, 2025
概括
增加tildrakizumab剂量改善了牛皮症状和代谢健康. 这种IL-23抑制剂的较高剂量显著降低了代谢综合征患者的胆固醇,LDL和葡萄糖水平.
科学领域:
- 皮肤病学 皮肤病学
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 牛皮与代谢综合征和心血管风险增加有关.
- 作为IL-23抑制剂的提尔德拉基祖马布可能会影响代谢参数.
- 调查tildrakizumab对牛皮患者代谢健康的影响至关重要.
研究的目的:
- 评估提升蒂尔德拉基祖马布剂量对脂质和葡萄糖水平的影响.
- 为了评估患有代谢综合征的牛皮病患者的代谢变化和对标准蒂尔德拉基祖马布剂量的部分反应.
主要方法:
- 一项为期52周的前性研究,涉及25名患有代谢综合征的牛皮病患者.
- 患者接受了100毫克的蒂德拉基祖马布,部分响应者 (PASI>2) 在第16周切换到200毫克.
- 测量包括PASI,DLQI,总胆固醇,LDL和葡萄糖在基线和16周和40周.
主要成果:
- 100毫克的剂量在第16周没有显著的代谢变化.
- 切换到200毫克的蒂德拉基祖马布可显著降低40周的总胆固醇,LDL和葡萄糖 (p <0.05).
- 还观察到PASI和DLQI的显著改善 (p < 0.05).
结论:
- 较高的蒂德拉基祖马布剂量 (200毫克) 在部分响应者中改善了皮肤严重性和代谢资料.
- 这项研究表明,蒂尔德拉基祖马布对代谢参数的潜在剂量依赖作用.
- 增强IL-23抑制可能有助于改善牛皮患者的代谢健康.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244


